BMY BRISTOL MYERS SQUIBB CO
Pharmaceutical Preparations · NYSE · SEC CIK 14272 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.2%
TTM net income YoY53.1%
TTM EPS YoY51.9%
Revenue 3-yr CAGR3.6%
Net income 3-yr CAGR3.7%
Margins
Gross margin69.2%
Operating margin—
Net margin18.5%
FCF margin18.6%
EBITDA margin—
Returns
ROE44.1%
ROA10.0%
ROIC (approx.)—
Asset turnover0.54x
Leverage & solvency
Liabilities / assets73.6%
Debt / equity1.83x
Current ratio1.59x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.15x
Accruals ratio-1.5%
Payout ratio55.4%
Capex / revenue2.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Cost of revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B |
| Gross profit | $34.26B | $34.33B | $34.31B | $36.02B | $36.45B |
| R&D expense | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B |
| SG&A expense | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B |
| Interest expense | $1.89B | $1.95B | $1.17B | $1.23B | $1.33B |
| Pretax income | $9.33B | -$8.38B | $8.44B | $7.71B | $8.10B |
| Income tax | $2.27B | $554.00M | $400.00M | $1.37B | $1.08B |
| Net income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B |
| EPS (basic) | 3.47 | -4.41 | 3.88 | 2.97 | 3.15 |
| EPS (diluted) | 3.46 | -4.41 | 3.86 | 2.95 | 3.12 |
| Dividends declared per share | 2.49 | 2.42 | 2.31 | 2.19 | 2.01 |
| Weighted avg. shares (diluted) | 2.04B | 2.03B | 2.08B | 2.15B | 2.25B |
| Balance sheet | |||||
| Cash & equivalents | $10.21B | $10.35B | $11.52B | $9.32B | $14.32B |
| Short-term investments | $464.00M | $513.00M | $816.00M | $130.00M | $2.99B |
| Receivables | $9.59B | $9.01B | $8.88B | $8.15B | $7.98B |
| Inventory | $2.69B | $2.56B | $2.66B | $2.34B | $2.10B |
| Current assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B |
| PP&E, net | $7.54B | $7.14B | $6.65B | $6.25B | $6.05B |
| Goodwill | $21.75B | $21.72B | $21.17B | $21.15B | $20.50B |
| Intangibles | $19.10B | $23.31B | $27.07B | $35.86B | $42.53B |
| Total assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B |
| Current liabilities | $23.42B | $23.77B | $22.26B | $21.89B | $21.87B |
| Short-term debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B |
| Long-term debt | $42.85B | $47.60B | $36.65B | $35.06B | $39.60B |
| Total debt | $45.11B | $49.65B | $39.77B | $39.32B | $44.55B |
| Total liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B |
| Shareholders' equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B |
| Net debt | $34.90B | $39.30B | $28.25B | $30.00B | $30.24B |
| Cash flow statement | |||||
| Operating cash flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B |
| Capital expenditure | $1.31B | $1.25B | $1.21B | $1.12B | $973.00M |
| Free cash flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
| Investing cash flow | -$4.13B | -$21.35B | -$2.29B | -$1.06B | -$538.00M |
| Financing cash flow | -$10.35B | $5.13B | -$9.42B | -$16.96B | -$16.22B |
| Depreciation & amortization | $4.01B | $9.60B | $9.76B | $10.28B | $10.69B |
| Stock-based compensation | $553.00M | $507.00M | $518.00M | $457.00M | $583.00M |
| Dividends paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B |
| Share buybacks | $0 | $0 | $5.16B | $8.00B | $6.29B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.